Donna Roy Grogan

CIK: 0001788455

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)11 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CCCC

C4 Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (11 total)

CCCC
C4 Therapeutics, Inc.
Oct 1, 2026
Award(A)
Direct
4.6K shares at avg. $3.14$15K
CCCC
C4 Therapeutics, Inc.
Jul 1, 2026
Award(A)
Direct
3.3K shares at avg. $4.34$14K
CCCC
C4 Therapeutics, Inc.
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
62K shares-
CCCC
C4 Therapeutics, Inc.
Apr 1, 2026
Award(A)
Direct
5.4K shares at avg. $2.70$14K
CCCC
C4 Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
7.5K shares at avg. $1.93$15K
CCCC
C4 Therapeutics, Inc.
Oct 1, 2025
Award(A)
Direct
6.7K shares at avg. $2.15$14K
CCCC
C4 Therapeutics, Inc.
Jul 1, 2025
Award(A)
Direct
9.6K shares at avg. $1.51$15K
CCCC
C4 Therapeutics, Inc.
Jun 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
35.5K shares-
CCCC
C4 Therapeutics, Inc.
Apr 1, 2025
Award(A)
Direct
9.6K shares at avg. $1.44$14K
CCCC
C4 Therapeutics, Inc.
Jan 2, 2025
Award(A)
Direct
3.8K shares at avg. $3.66$14K
CCCC
C4 Therapeutics, Inc.
Oct 1, 2024
Award(A)
Direct
2.5K shares at avg. $5.56$14K

		Type	Shares	Price		Ownership
Oct 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	4,618	$3.14	$14,501	Direct
Jul 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	3,341	$4.34	$14,500	Direct
Jun 24, 2026	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	62,000	-	-	Direct
Apr 1, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	5,370	$2.70	$14,499	Direct
Jan 2, 2026	CCCC C4 Therapeutics, Inc.	Award(A)	7,513	$1.93	$14,500	Direct
Oct 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	6,740	$2.15	$14,491	Direct
Jul 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	9,609	$1.51	$14,510	Direct
Jun 18, 2025	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	35,500	-	-	Direct
Apr 1, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	9,581	$1.44	$13,749	Direct
Jan 2, 2025	CCCC C4 Therapeutics, Inc.	Award(A)	3,757	$3.66	$13,751	Direct
Oct 1, 2024	CCCC C4 Therapeutics, Inc.	Award(A)	2,474	$5.56	$13,755	Direct

1-11 of 11 transactions

About GROGAN DONNA ROY

GROGAN DONNA ROY (SEC CIK 0001788455) files insider reports with the SEC as Director of C4 Therapeutics, Inc. (CCCC).

Signal8 holds 11 ownership filings by GROGAN DONNA ROY, all Form 4s, filed between Oct 2, 2024 and Oct 2, 2026. Those filings report 11 transactions, from Oct 1, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on GROGAN DONNA ROY's filings is in WATERTOWN, MA.

Recent filings by GROGAN DONNA ROY

Oct 1, 2026: Grant or award of CCCC shares (Form 4, code A).
Jul 1, 2026: Grant or award of CCCC shares (Form 4, code A).
Jun 24, 2026: Grant or award of CCCC derivative securities (Form 4, code A).
Apr 1, 2026: Grant or award of CCCC shares (Form 4, code A).
Jan 2, 2026: Grant or award of CCCC shares (Form 4, code A).

Other insiders filing for C4 Therapeutics, Inc. (CCCC)

Anderson Kenneth Carl, Director
Adams Kendra, Chief Financial Officer
REYNO LEONARD, Chief Medical Officer
Hughes Owen, Director
Hoerter Steven L., Director
Koppikar Utpal, Director

How to read Form 4 transaction codes